Therapeutic Approaches in Pulmonary Arterial Hypertension with Beneficial Effects on Right Ventricular Function-Preclinical Studies

Int J Mol Sci. 2023 Oct 24;24(21):15539. doi: 10.3390/ijms242115539.

Abstract

Pulmonary hypertension (PH) is a progressive condition that affects the pulmonary vessels, but its main prognostic factor is the right ventricle (RV) function. Many mice/rat models are used for research in PAH, but results fail to translate to clinical trials. This study reviews studies that test interventions on pulmonary artery banding (PAB), a model of isolated RV disfunction, and PH models. Multiple tested drugs both improved pulmonary vascular hemodynamics in PH models and improved RV structure and function in PAB animals. PH models and PAB animals frequently exhibited similar results (73.1% concordance). Macitentan, sildenafil, and tadalafil improved most tested pathophysiological parameters in PH models, but almost none in PAB animals. Results are frequently not consistent with other studies, possibly due to the methodology, which greatly varied. Some research groups start treating the animals immediately, and others wait up to 4 weeks from model induction. Treatment duration and choice of anaesthetic are other important differences. This review shows that many drugs currently under research for PAH have a cardioprotective effect on animals that may translate to humans. However, a uniformization of methods may increase comparability between studies and, thus, improve translation to clinical trials.

Keywords: preclinical studies; pulmonary arterial banding; pulmonary arterial hypertension; right ventricle.

Publication types

  • Review

MeSH terms

  • Animals
  • Disease Models, Animal
  • Familial Primary Pulmonary Hypertension
  • Humans
  • Hypertension, Pulmonary* / drug therapy
  • Mice
  • Pulmonary Arterial Hypertension* / drug therapy
  • Pulmonary Artery
  • Rats
  • Ventricular Function, Right